Literature DB >> 34520

Electrophysiologic properties of intravenous Tenormine in man.

M Di Biase, S Favale, P Rizzon.   

Abstract

The acute electrophysiologic effects of intravenous Tenormine (0.1 mg/kg body weight), a new cardioselective beta-adrenoreceptor blocking drug, were studied in 18 subjects with estimated normal impulse formation and conduction. The most significant (P less than 0.01) effects were sinus cycle lengthening, depression of intranodal conduction and prolongation of AV node refractory periods. Sinus node recovery time, sinoatrial conduction time and atrial refractory periods were only slightly prolonged (P less than 0.05). Intraatrial conduction and infra-His conduction were unchanged. These properties are compared with those of the most commonly employed beta-blocking agents. The clinical implications are discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 34520

Source DB:  PubMed          Journal:  Eur J Cardiol        ISSN: 0301-4711


  4 in total

1.  Long-term efficacy and safety of atenolol for supraventricular tachycardia in children.

Authors:  A V Mehta; A B Subrahmanyam; R Anand
Journal:  Pediatr Cardiol       Date:  1996 Jul-Aug       Impact factor: 1.655

2.  Electrophysiological effects of cardioselective and non-cardioselective beta-adrenoceptor blockers with and without ISA at rest and during exercise.

Authors:  V Hombach; V Braun; H W Höpp; D Gil-Sanchez; D W Behrenbeck; M Tauchert; H H Hilger
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

Review 3.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

4.  Antiarrhythmic effects of acute betablockade with atenolol on supraventricular tachycardias at rest and during exercise.

Authors:  V Hombach; V Braun; H W Höpp; D Gil-Sanchez; D W Behrenbeck; M Tauchert; H H Hilger
Journal:  Klin Wochenschr       Date:  1981-02-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.